Author

Britta Siegmund

Early disease control in UC and CD
Early disease control in UC and CD

Britta Siegmund  et al.

Targeted oral therapies for the treatment of moderate to severe UC (Bristol Myers Squibb)
Targeted oral therapies for the treatment of moderate to severe UC (Bristol Myers Squibb)

Britta Siegmund  et al.

New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)
New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)

Britta Siegmund  et al.

Luminal CD / Luminal CD: Assess, treat, repeat
Luminal CD / Luminal CD: Assess, treat, repeat

Britta Siegmund  et al.

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Britta Siegmund  et al.

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Personalised therapy of IBD: Already clinical practice?
Personalised therapy of IBD: Already clinical practice?

Britta Siegmund

Phenotypic, genetic and immunologic disease classification: More than CD and CU
Phenotypic, genetic and immunologic disease classification: More than CD and CU

Britta Siegmund

The role of host immunity in triggering chronic intestinal disorders
The role of host immunity in triggering chronic intestinal disorders

Britta Siegmund

Mesentery as a key player in Crohn's
Mesentery as a key player in Crohn's

Britta Siegmund

DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE
DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE

Britta Siegmund  et al.

FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS
FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS

Britta Siegmund  et al.

EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Britta Siegmund  et al.

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)
Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

Britta Siegmund  et al.

Item 1 - 14 / 14
1